These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature. Roccatello D; Sciascia S; Di Simone D; Solfietti L; Naretto C; Fenoglio R; Baldovino S; Menegatti E Autoimmun Rev; 2016 Jun; 15(6):529-38. PubMed ID: 26876383 [TBL] [Abstract][Full Text] [Related]
3. Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study. Irazabal MV; Eirin A; Lieske J; Beck LH; Sethi S; Borland TM; Dillon JJ; Nachman PH; Nasr SH; Cornell LD; Leung N; Cattran DC; Fervenza FC Nephrol Dial Transplant; 2013 Jan; 28(1):137-46. PubMed ID: 22987142 [TBL] [Abstract][Full Text] [Related]
4. Rituximab for the second- and third-line therapy of idiopathic membranous nephropathy: a prospective single center study using a new treatment strategy. Busch M; Rüster C; Schinköthe C; Gerth J; Wolf G Clin Nephrol; 2013 Aug; 80(2):105-13. PubMed ID: 23587125 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis. Lu W; Gong S; Li J; Luo H; Wang Y Medicine (Baltimore); 2020 Apr; 99(16):e19804. PubMed ID: 32311997 [TBL] [Abstract][Full Text] [Related]
6. A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR). Fervenza FC; Canetta PA; Barbour SJ; Lafayette RA; Rovin BH; Aslam N; Hladunewich MA; Irazabal MV; Sethi S; Gipson DS; Reich HN; Brenchley P; Kretzler M; Radhakrishnan J; Hebert LA; Gipson PE; Thomas LF; McCarthy ET; Appel GB; Jefferson JA; Eirin A; Lieske JC; Hogan MC; Greene EL; Dillon JJ; Leung N; Sedor JR; Rizk DV; Blumenthal SS; Lasic LB; Juncos LA; Green DF; Simon J; Sussman AN; Philibert D; Cattran DC; Nephron; 2015; 130(3):159-68. PubMed ID: 26087670 [TBL] [Abstract][Full Text] [Related]
7. Rituximab in idiopathic membranous nephropathy. Ruggenenti P; Cravedi P; Chianca A; Perna A; Ruggiero B; Gaspari F; Rambaldi A; Marasà M; Remuzzi G J Am Soc Nephrol; 2012 Aug; 23(8):1416-25. PubMed ID: 22822077 [TBL] [Abstract][Full Text] [Related]
8. Optimized rituximab regimen versus recommended regimen for idiopathic membranous nephropathy: A single-center retrospective cohort study. Yan P; Fang X; Ke B Int Immunopharmacol; 2024 Mar; 130():111718. PubMed ID: 38377859 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of low or standard rituximab-based protocols and comparison to Ponticelli's regimen in membranous nephropathy. Fenoglio R; Baldovino S; Sciascia S; De Simone E; Del Vecchio G; Ferro M; Quattrocchio G; Naretto C; Roccatello D J Nephrol; 2021 Apr; 34(2):565-571. PubMed ID: 32594370 [TBL] [Abstract][Full Text] [Related]
11. Low-dose rituximab is poorly effective in patients with primary membranous nephropathy. Moroni G; Depetri F; Del Vecchio L; Gallelli B; Raffiotta F; Giglio E; Brunini F; D'Amico M; Longhi S; Radice A; Messa P; Sinico RA Nephrol Dial Transplant; 2017 Oct; 32(10):1691-1696. PubMed ID: 27387472 [TBL] [Abstract][Full Text] [Related]
12. [Treatment of children with steroid-dependent nephrotic syndrome with rituximab]. Huang J; Du J; Wang S; Xiao L; Zhao X Zhonghua Er Ke Za Zhi; 2014 Jul; 52(7):521-4. PubMed ID: 25224058 [TBL] [Abstract][Full Text] [Related]
13. Rituximab may affect T lymphocyte subsets balance in primary membranous nephropathy. Zhang Y; Yang J; Li J; Sun J; Zhou L; Xu D; Sha W; Dai L; Shen L BMC Nephrol; 2024 Mar; 25(1):86. PubMed ID: 38448810 [TBL] [Abstract][Full Text] [Related]
15. Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy. van den Brand JAJG; Ruggenenti P; Chianca A; Hofstra JM; Perna A; Ruggiero B; Wetzels JFM; Remuzzi G J Am Soc Nephrol; 2017 Sep; 28(9):2729-2737. PubMed ID: 28487395 [TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Alberici F; Smith RM; Jones RB; Roberts DM; Willcocks LC; Chaudhry A; Smith KG; Jayne DR Rheumatology (Oxford); 2015 Jul; 54(7):1153-60. PubMed ID: 25477054 [TBL] [Abstract][Full Text] [Related]
17. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. Fervenza FC; Appel GB; Barbour SJ; Rovin BH; Lafayette RA; Aslam N; Jefferson JA; Gipson PE; Rizk DV; Sedor JR; Simon JF; McCarthy ET; Brenchley P; Sethi S; Avila-Casado C; Beanlands H; Lieske JC; Philibert D; Li T; Thomas LF; Green DF; Juncos LA; Beara-Lasic L; Blumenthal SS; Sussman AN; Erickson SB; Hladunewich M; Canetta PA; Hebert LA; Leung N; Radhakrishnan J; Reich HN; Parikh SV; Gipson DS; Lee DK; da Costa BR; Jüni P; Cattran DC; N Engl J Med; 2019 Jul; 381(1):36-46. PubMed ID: 31269364 [TBL] [Abstract][Full Text] [Related]
18. Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series. Cortazar FB; Leaf DE; Owens CT; Laliberte K; Pendergraft WF; Niles JL BMC Nephrol; 2017 Feb; 18(1):44. PubMed ID: 28143416 [TBL] [Abstract][Full Text] [Related]
19. A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy. Boumpas DT; Tassiulas IO; Fleisher TA; Vaughan E; Piscitelli S; Kim Y; Pucino F; Balow JE; Austin HA Clin Nephrol; 1999 Aug; 52(2):67-75. PubMed ID: 10480216 [TBL] [Abstract][Full Text] [Related]
20. Therapy of Rituximab in Idiopathic Membranous Nephropathy with Nephrotic Syndrome: A Systematic Review and Meta-analysis. Zou PM; Li H; Cai JF; Chen ZJ; Li C; Li XW Chin Med Sci J; 2018 Mar; 33(1):9-19. PubMed ID: 29620510 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]